C端结合蛋白2是一种靶向多发性骨髓瘤MYC-IRF4轴的新型抑癌因子
多发性骨髓瘤细胞依赖MYC及其直接反式激活靶点IRF4增殖存活,两者均难以直接成药。研究揭示CTBP2在骨髓瘤中频繁下调并与生存缩短、高增殖及不良临床结局相关,恢复CTBP2可在体外和体内产生抗肿瘤效应并抑制MYC-IRF4网络,机制涉及H3K27ac去乙酰化及激活IFIT3,多梳介导沉默和DNA甲基化参与CTBP2失活,EZH2、HDAC和DNMT抑制剂可恢复其表达。
要点
- CTBP2在骨髓瘤中频繁下调,与生存缩短、高增殖特征和不良临床结局相关。
- 恢复CTBP2在体外和体内均产生抗肿瘤效应,显著抑制MYC-IRF4网络基因。
- EZH2、HDAC和DNA甲基转移酶抑制剂可有效恢复骨髓瘤中CTBP2表达。
核心结论
- CTBP2缺失在多发性骨髓瘤发生中起重要作用,并揭示MYC-IRF4失调的又一机制。
研究设计与样本
- 基础研究,涉及多发性骨髓瘤细胞及体内外实验,具体样本量原文未报告。
主要发现
- 与上皮性癌症相反,CTBP2在多发性骨髓瘤中频繁下调,与生存缩短、高增殖特征和不良临床结局相关。
- 恢复CTBP2在体外和体内均表现出强效抗肿瘤作用,并显著抑制MYC-IRF4网络基因。
- CTBP2通过组蛋白H3赖氨酸27去乙酰化(H3K27ac)及激活MYC抑制因子IFIT3间接阻碍MYC和IRF4转录。
- CTBP2激活干扰素基因特征,提示其在骨髓瘤中兼具免疫调节作用。
- 表观遗传研究显示多梳介导沉默和DNA甲基化参与骨髓瘤中CTBP2失活。
关键数值与推荐
- 增强子zeste同源物2(EZH2)、组蛋白去乙酰化酶(HDAC)和DNA甲基转移酶抑制剂可有效恢复骨髓瘤中CTBP2表达。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) cells are addicted to MYC and its direct transactivation targets IRF4 for proliferation and survival. MYC and IRF4 are still considered "undruggable," as most small-molecule inhibitors suffer from low potency, suboptimal pharmacokinetic properties, and undesirable off-target effects. Indirect inhibition of MYC/IRF4 emerges as a therapeutic vulnerability in MM. Here, we uncovered an unappreciated tumor-suppressive role of C-terminal binding protein 2 (CTBP2) in MM via strong inhibition of the MYC-IRF4 axis. In contrast to epithelial cancers, CTBP2 is frequently downregulated in MM, in association with shortened survival, hyperproliferative features, and adverse clinical outcomes. Restoration of CTBP2 exhibited potent antitumor effects against MM in vitro and in vivo, with marked repression of the MYC-IRF4 network genes. Mechanistically, CTBP2 impeded the transcription of MYC and IRF4 by histone H3 lysine 27 deacetylation (H3K27ac) and indirectly via activation of the MYC repressor IFIT3. In addition, activation of the interferon gene signature by CTBP2 suggested its concomitant immunomodulatory role in MM. Epigenetic studies have revealed the contribution of polycomb-mediated silencing and DNA methylation to CTBP2 inactivation in MM. Notably, inhibitors of Enhance of zeste homolog 2, histone deacetylase, and DNA methyltransferase, currently under evaluation in clinical trials, were effective in restoring CTBP2 expression in MM. Our findings indicated that the loss of CTBP2 plays an essential role in myelomagenesis and deciphers an additional mechanistic link to MYC-IRF4 dysregulation in MM. We envision that the identification of novel critical regulators will facilitate the development of selective and effective approaches for treating this MYC/IRF4-addicted malignancy.
引用
- Cheung CHY, Cheng CK, Leung KT, et al. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma. Blood Adv. 2024. PMID: 38457926. doi:10.1182/bloodadvances.2023010218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。